Atorvastatin Enhance Efficacy of Mesenchymal Stem Cells Treatment for Swine Myocardial Infarction via Activation of Nitric Oxide Synthase

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Song, Lei ^a   Yang, Yue Jin ^a   Dong, Qiu Ting ^a   Qian, Hai Yan ^a   Gao, Run Lin ^a   Qiao, Shu Bin ^a   Shen, Rui ^a   He, Zuo Xiang ^a   Lu, Min Jie ^a   Zhao, Shi Hua ^a   Geng, Yong Jian ^b   Gersh, Bernard J ^c  

^a FUWAI HOSPITAL   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOR; ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FIBROSIS; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; APOPTOSIS; C-REACTIVE PROTEIN; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FIBROSIS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOCARDIAL INFARCTION; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PYRROLES; SWINE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR FUNCTION, LEFT;

ANIMALIA; SUIDAE;

EID: 84878607366     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065702     Document Type: Article

References (35)

1. Psaltis PJ, Zannettino A, Worthley SG, Gronthos S, (2008) Mesenchymal Stromal Cells- Potential for Cardiovascular Repair. Stem Cells 29: 2201-2210.
2. Robey TE, Saiget MK, Reinecke H, Murry CE, (2008) Systems approaches to preventing transplanted cell death in cardiac repair. J Mol Cell Cardiol 45: 567-581.
3. Pons J, Huang Y, Arakawa-Hoyt J, Washko D, Takagawa J, et al. (2008) VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun 376: 419-422.
4. Yang YJ, Qian HY, Huang J, Geng YJ, Gao RL, et al. (2008) Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 29: 1578-1590.
5. Blum A, Shamburek R, (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203: 325-330.
6. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG, (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8: e1000412.
7. Rho GJ, Kumar BM, Balasubramanian SS, (2009) Porcine mesenchymal stem cells-current technological status and future perspective. Front Biosci 14: 3942-3961.
8. van den Bos EJ, Thompson RB, Wagner A, Mahrholdt H, Morimoto Y, et al. (2005) Functional assessment of myoblast transplantation for cardiac repair with magnetic resonance imaging. Eur J Heart Fail 7: 435-443.
9. Volz HC, Buss SJ, Li J, Goser S, Andrassy M, et al. (2011) Autoimmunity against cardiac troponin I in ischaemia reperfusion injury. Eur J Heart Fail 13: 1052-1059.
10. Weber KT, Pick R, Silver MA, Moe GW, Janicki JS, et al. (1990) Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation 82: 1387-1401.
11. Forte A, Galderisi U, Cipollaro M, Cascino A, (2009) Mesenchymal stem cells: a good candidate for restenosis therapy? Curr Vasc Pharmacol 7: 381-393.
12. Yang YJ, Zhao JL, You SJ, Wu YJ, Jing ZC, et al. (2007) Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATP channel. Eur J Heart Fail 9: 30-36.
13. Qian HY, Yang YJ, Huang J, Gao RL, Dou KF, et al. (2007) Effects of Tongxinluo-facilitated cellular cardiomyoplasty with autologous bone marrow-mesenchymal stem cells on postinfarct swine hearts. Chin Med J (Engl) 120: 1416-1425.
14. Yang YJ, Qian HY, Huang J, Li JJ, Gao RL, et al. (2009) Combined Therapy With Simvastatin and Bone Marrow-Derived Mesenchymal Stem Cells Increases Benefits in Infarcted Swine Hearts. Arterioscler Thromb Vasc Biol 29: 2076-2082.
15. Dai W, Hale SL, Martin BJ, Kuang JQ, Dow JS, et al. (2005) Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation 112: 214-223.
16. Cannon RO 3rd (2005) Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2: 88-94.
17. Jiang CY, Gui C, He AN, Hu XY, Chen J, et al. (2008) Optimal time for mesenchymal stem cell transplantation in rats with myocardial infarction. J Zhejiang Univ Sci B 9: 630-637.
18. Wolf D, Reinhard A, Seckinger A, Katus HA, Kuecherer H, et al. (2009) Dose-dependent effects of intravenous allogeneic mesenchymal stem cells in the infarcted porcine heart. Stem Cells Dev 18: 321-329.
19. Chen SL, Fang WW, Qian J, Ye F, Liu YH, et al. (2004) Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 117: 1443-1448.
20. Katritsis DG, Sotiropoulou PA, Karvouni E, Karabinos I, Korovesis S, et al. (2005) Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 65: 321-329.
21. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, et al. (2006) Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther 20: 27-36.
22. Cao QL, Onifer SM, Whittemore SR, (2008) Labeling stem cells in vitro for identification of their differentiated phenotypes after grafting into the CNS. Methods Mol Biol 438: 361-374.
23. Nyolczas N, Charwat S, Posa A, Hemetsberger R, Pavo N, et al. (2009) Tracking the migration of cardially delivered therapeutic stem cells in vivo: state of the art. Regen Med 4: 407-422.
24. Weir C, Morel-Kopp MC, Gill A, Tinworth K, Ladd L, et al. (2008) Mesenchymal stem cells: isolation, characterisation and in vivo fluorescent dye tracking. Heart Lung Circ 17: 395-403.
25. Li L, Zhang S, Zhang Y, Yu B, Xu Y, et al. (2009) Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure. Mol Biol Rep 36: 725-731.
26. Caplan AI, (2009) Why are MSCs therapeutic? New data: new insight. J Pathol 217: 318-324.
27. Forrester JS, White AJ, Matsushita S, Chakravarty T, Makkar RR, (2009) New paradigms of myocardial regeneration post-infarction: tissue preservation, cell environment, and pluripotent cell sources. JACC Cardiovasc Interv 2: 1-8.
28. Southan GJ, Szabo C, (1996) Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 51: 383-394.
29. Buxton IL, Cheek DJ, Eckman D, Westfall DP, Sanders KM, et al. (1993) NG-nitro L-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. Circ Res 72: 387-395.
30. Gonon AT, Widegren U, Bulhak A, Salehzadeh F, Persson J, et al. (2008) Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide. Cardiovasc Res 78: 116-122.
31. Ohkawara H, Ishibashi T, Saitoh S, Inoue N, Sugimoto K, et al. (2010) Preventive effects of pravastatin on thrombin-triggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo. Cardiovasc Res 88: 492-501.
32. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, et al. (2001) HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108: 391-397.
33. Xu R, Chen J, Cong X, Hu S, Chen X, (2008) Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2. J Cell Biochem 103: 256-269.
34. Chen Z, Peng IC, Sun W, Su MI, Hsu PH, et al. (2009) AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 104: 496-505.
35. Dong Q, Yang Y, Song L, Qian H, Xu Z, (2010) Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating amp-activated protein kinase. Int J Cardiol 153: 311-316.